Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3
PHASE4CompletedINTERVENTIONAL
Enrollment
392
Participants
Timeline
Start Date
April 30, 2004
Study Completion Date
October 31, 2006
Conditions
Hepatitis C Virus
Interventions
DRUG
Peginterferon alfa-2a 40KD and Ribavirin
Trial Locations (1)
SE-413 45
Göteborg University, Gothenburg
All Listed Sponsors
lead
NORDynamIC Study Group
OTHER
NCT00143000 - Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3 | Biotech Hunter | Biotech Hunter